Journal of Cancer Research and Therapeutics Close
 

Table 5: 2nd line comparative activity in terms of progression-free survival of monoclonal antibody check point Inhibitors in nonsmall cell lung cancer

Table 5: 2<sup>nd</sup> line comparative activity in terms of progression-free survival of monoclonal antibody check point Inhibitors in nonsmall cell lung cancer